-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 24th, Biotech announced that the company has recently received a "Drug Supplementary Application for Adalimumab Injection (trade name: Glerli®) approved and issued by the National Medical Products Administration ("National Medical Products Administration").
Glerli® is a biosimilar of adalimumab developed by the company, which is a recombinant fully human monoclonal antibody expressed by CHO cells.